Appendix-derived Pseudomyxoma Peritonei (PMP): Molecular profiling toward treatment of a rare malignancy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 41, Issue 8, 2018, Pages 777-783

  Gleeson, Elizabeth M ^a   Feldman, Rebecca ^b   Mapow, Beth L ^a   Mackovick, Lynn T ^a   Ward, Kristine M ^a   Morano, William F ^a   Rubin, Rene R ^a   Bowne, Wilbur B ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b LEVINE CANCER INSTITUTE   (United States)

Author keywords

biomarkers; DPAM; gene mutations; IHC; Molecular profiling; PMCA; pseudomyxoma peritonei

Indexed keywords

APC PROTEIN; ATM PROTEIN; B RAF KINASE; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MUTL PROTEIN HOMOLOG 1; OXALIPLATIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN P53; SMAD4 PROTEIN; TUMOR MARKER;

ADULT; AGED; APPENDIX; CANCER CLASSIFICATION; CANCER THERAPY; CELL PROLIFERATION; CHEMOSENSITIVITY; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; NEXT GENERATION SEQUENCING; PERITONEUM PSEUDOMYXOMA; PROTEIN EXPRESSION; SANGER SEQUENCING; FOLLOW UP; GENE EXPRESSION PROFILING; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PATIENT SELECTION; PERITONEUM TUMOR; PROCEDURES;

AGED; APPENDIX; BIOMARKERS, TUMOR; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; PATIENT SELECTION; PERITONEAL NEOPLASMS; PSEUDOMYXOMA PERITONEI;

EID: 85014549308     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0000000000000376     Document Type: Conference Paper

References (37)

1. Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449-2456.
2. Miner TJ, Shia J, Jaques DP, et al. Long-term survival following treatment of pseudomyxoma peritonei. Ann Surg. 2005;241: 300-308.
3. Kusamura S, O'Dwyer ST, Baratti D, et al. Techinical aspects of cytoreductive surgery. J Surg Oncol. 2008;98:232-236.
4. Esquivel J. Cytoreductive surgery for peritoneal malignancies- development of standards of care for the community. Surg Oncol Clin N Am. 2007;16:653-666.
5. Stamou KM, Karakozis S, Sugarbaker PH. Total abdominal colectomy, pelvic peritonectomy, and end-ileostomy for the surgical palliation of mucinous peritoneal carcinomatosis from non-gynecologic cancer. J Surg Oncol. 2003;83:197-203.
6. Gusani NJ, Cho SW, Colovos C, et al. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Ann Surg Oncol. 2007;15: 754-763.
7. Misdraji J, Yantiss RK, Graeme-Cook FM, et al. Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am J Surg Pathol. 2003;27:1089-1103.
8. Ronnett BM, Yan H, Kurman RJ, et al. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer. 2001;92:85-91.
9. Ronnett BM, Zahn CM, Kurman RJ, et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei". Am J Surg Pathol. 1995;19:1390-1408.
10. Shetty S, Natarajan B, Thomas P, et al. Proposed classification of pseudomyxoma peritonei: influence of signet ring cells on survival. Am Surgeon. 2013;7:1171-1176.
11. Bradley RF, Stewart JH, Russell GB, et al. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol. 2006;30:551-559.
12. Marmor S, Portschy PR, Tuttle TM, et al. The rise in appendiceal cancer indicidence: 2000-2009. J Gastrointest Surg. 2015;19: 743-750.
13. Carr NJ, Finch J, Ilesley IC, et al. Pathology and prognosis in pseudomyxoma peritonei: a review of 274 cases. J Clin Pathol. 2012;65:919-923.
14. Liu X, Mody K, de Abreu FB, et al. Molecular Profiling of Appendiceal Epithelial Tumors Using Massively Parallel Sequencing to Identify Somatic Mutations. Clinl Chem. 2014;60:1004-1011.
15. Nummela P, Saarinen L, Thiel A, et al. Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry. Int J Cancer. 2015;136:E282-E289.
16. Millis SZ, Bryant D, Basu G, et al. Molecular profiling of infiltrating urothelial carcinoma of bladder and non-bladder origin. Clin Genitourin Cancer. 2015;13:e37-349.
17. Chang MS, Byeon SJ, Yoon SO, et al. Leptin, MUC2 and mTOR in Appendiceal Mucinous Neoplasms. Pathobiology. 2012;79: 45-53.
18. Noguchi R, Yano H, Gohda Y, et al. Molecular profiles of highgrade and low-grade pseudomyxoma peritonei. Cancer Med. 2015;4:1809-1816.
19. Davison JM, Hartman DA, Singhi AD, et al. Loss of SMAD4 protein expression is associated with high tumor grade and poor prognosis in disseminated appendiceal mucinous neoplasms. Am J Surg Pathol. 2014;38:583-592.
20. Jordheim LP, Sève P, Trédan O, et al. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol. 2011;12:693-702.
21. Besse B, Olaussen KA, Soria JC. ERCC1 and RRM1: ready for prime time? J Clin Oncol. 2013;31:1050-1060.
22. Langer CJ. Exploring biomarkers in head and neck cancer. Cancer. 2012;118:3882-3892.
23. Sève P, Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol. 2008;9: 168-175.
24. Wilson PM, Danenberg PV, Johnston PG, et al. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat Rev Clin Oncol. 2014;11:282-298.
25. Schmidt KT, Chau CH, Price DK, et al. Precision oncology medicine: the clinical relevance of patient specific biomarkers used to optimize cancer treatment. J Clin Pharmacol. 2016;56: 1484-1499.
26. Wang LW, Hsiao CF, Chen WT, et al. Celecoxib plus chemoradiotherapy for locally advanced rectal cancer: a phase II TCOG study. J Surg Oncol. 2014;109:580-585.
27. Sennino B, Ishiguro-Oonuma T, Wei Y, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov. 2012;2:270-287.
28. Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4: 915-925.
29. Ruiz-Tovar J, Teruel DG, Castin?eiras VM, et al. Mucocele of the appendix. World J Surg. 2007;31:542-548.
30. Taii A, Sakagami J, Shinoda M, et al. Pseudomyxoma peritonei occurring after an uneventful 23 years interval from appendectomy. Intern Med. 2007;46:1109-1112.
31. Gatalica Z, Loggie B. COX-2 expression in pseudomyxoma peritonei. Cancer Letters. 2006;244:86-90.
32. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol. 2009;27:5924-5930.
33. Alakus H, Babicky ML, Ghosh P, et al. Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin. Genome Med. 2014;6:43.
34. Singhi AD, Davison JM, Choudry HA, et al. GNAS is frequently mutated in both low-grade and high-grade disseminated appendiceal mucinous neoplasms but does not affect survival. Human Pathol. 2014;45:1737-1743.
35. Nishikawa G, Sekine S, Ogawa R, et al. Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms. Br J Cancer. 2013; 108:951-958.
36. Esquivel J, Garcia SS, Hicken W, et al. Evaluation of a New Staging Classification and a Peritoneal Surface Disease Severity Score (PSDSS) in 229 patients with mucinous appendiceal neoplams with or without peritoneal dissemination. J Surg Oncol. 2014;110:656-660.
37. Niedernhofer LJ, Odijk H, Budzowska M, et al. The structurespecific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-stranded breaks. Mol Cell Biol. 2004;24:5776-5787.